Specify a stock or a cryptocurrency in the search bar to get a summary
DiaMedica Therapeutics Inc
DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company develops treatments for neurological disorders and cardio-renal disease. Its lead candidate is DM199, a pharmaceutically active recombinant form of the kallikrein-1 protein for the treatment of acute ischemic stroke and other vascular diseases. It is also developing DM300 that is in preclinical stage of development for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Address: Two Carlson Parkway, Minneapolis, MN, United States, 55447
Analytics
WallStreet Target Price
8.33 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures DMAC
Dividend Analytics DMAC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DMAC
Stock Valuation DMAC
Financials DMAC
Results | 2019 | Dynamics |